Sanofi v. Watson Laboratories Inc., No. 16-2722 (Fed. Cir. Nov. 9, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Sanofi owns U.S. Patent Nos. 8,318,800 and 8,410,167, which describe and claim com positions and uses of the cardiovascular (specifically, antiarrhythmic) drug dronedarone . The ’800 patent , which expires in 2019, claims pharmaceutical compositions containing dronedarone. T he ’167 patent , which expires in 2029, claims methods of reducing hospitalization by administer- ing dronedarone to pa tients having specified characteris- tics. Sanofi’s subsidiary, Sanofi -Aventis U.S., LLC , received approval in mid -2009 for New Drug Application No.